Although the pro-inflammatory signaling does not seem to be related to the PD subtype and there is no evidence of a difference in the immune response between idiopathic PD, monogenic forms of PD (e.g., LRRK2-PD), and strong risk factor carriers such as GBA1-PD66, those PD subtypes present with different phenotypes and might need to be treated differently. The gene discussed is LRRK2; the disease is Parkinson disease.